Your browser doesn't support javascript.
loading
Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.
Davis, Carl W; Jackson, Katherine J L; McElroy, Anita K; Halfmann, Peter; Huang, Jessica; Chennareddy, Chakravarthy; Piper, Ashley E; Leung, Yvonne; Albariño, César G; Crozier, Ian; Ellebedy, Ali H; Sidney, John; Sette, Alessandro; Yu, Tianwei; Nielsen, Sandra C A; Goff, Arthur J; Spiropoulou, Christina F; Saphire, Erica Ollman; Cavet, Guy; Kawaoka, Yoshihiro; Mehta, Aneesh K; Glass, Pamela J; Boyd, Scott D; Ahmed, Rafi.
Afiliación
  • Davis CW; Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Jackson KJL; Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
  • McElroy AK; Viral Special Pathogens Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Pediatric Infectious Disease, Emory University, Atlanta, GA, USA; Division of Pediatric Infectious Disease, University of Pittsburgh, Pittsburgh, PA, USA.
  • Halfmann P; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA.
  • Huang J; Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Chennareddy C; Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
  • Piper AE; Virology Division, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD, USA.
  • Leung Y; Atreca, Redwood City, CA, USA.
  • Albariño CG; Viral Special Pathogens Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Crozier I; Integrated Research Facility at Fort Detrick, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institutes, Frederick, MD, USA.
  • Ellebedy AH; Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA; Division of Immunobiology, Department of Pathology and Immunology Washington University School of Medicine, St. Louis, MO, USA.
  • Sidney J; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.
  • Sette A; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Yu T; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Nielsen SCA; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Goff AJ; Virology Division, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD, USA.
  • Spiropoulou CF; Viral Special Pathogens Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Saphire EO; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Cavet G; Atreca, Redwood City, CA, USA.
  • Kawaoka Y; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA; Division of Virology, Department of Microbiology and Immunology, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Mehta AK; Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA, USA.
  • Glass PJ; Virology Division, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD, USA.
  • Boyd SD; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Ahmed R; Emory Vaccine Center and Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA. Electronic address: rahmed@emory.edu.
Cell ; 177(6): 1566-1582.e17, 2019 05 30.
Article en En | MEDLINE | ID: mdl-31104840
ABSTRACT
Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but their subclass composition changed over time, with IgG1 persisting, IgG3 rapidly declining, and IgG4 appearing late. Striking changes occurred in the immunoglobulin repertoire, with massive recruitment of naive B cells that subsequently underwent hypermutation. We characterized a large panel of EBOV glycoprotein-specific monoclonal antibodies (mAbs). Only a small subset of mAbs that bound glycoprotein by ELISA recognized cell-surface glycoprotein. However, this subset contained all neutralizing mAbs. Several mAbs protected against EBOV disease in animals, including one mAb that targeted an epitope under evolutionary selection during the 2014 outbreak. Convergent antibody evolution was seen across multiple donors, particularly among VH3-13 neutralizing antibodies specific for the GP1 core. Our study provides a benchmark for assessing EBOV vaccine-induced immunity.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos B / Fiebre Hemorrágica Ebola / Anticuerpos Monoclonales Tipo de estudio: Observational_studies Límite: Adult / Animals / Female / Humans / Male Idioma: En Revista: Cell Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos B / Fiebre Hemorrágica Ebola / Anticuerpos Monoclonales Tipo de estudio: Observational_studies Límite: Adult / Animals / Female / Humans / Male Idioma: En Revista: Cell Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos